Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 1 |
3. Spinal muscular atrophy
Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-006781-21-DK (EUCTR) | 20/12/2022 | Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 in Clinical Trials | Long-term follow-up of patients with spinal muscular atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials | Spinal Muscular Atrophy MedDRA version: 20.1;Level: PT;Classification code 10041582;Term: Spinal muscular atrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion Product Name: OAV101 Product Code: OAV101 Trade Name: Zolgensma 2 x 1013 vg (vector genomes)/mL solution for infusion Product Name: OAV101 Product Code: OAV101 | Novartis Pharma AG | NULL | NA | Female: yes Male: yes | 260 | Phase 4 | United States;Saudi Arabia;Taiwan;Greece;Thailand;Spain;Colombia;Switzerland;Italy;India;France;Malaysia;Viet Nam;Australia;Denmark;South Africa;Netherlands;China;United Kingdom;Egypt;Mexico;Canada;Belgium;Brazil;Singapore;Germany;Japan |